SHORT COMMUNICATION

FeF3 catalyzed cascade C–C and C–N bond formation: synthesis of differentially substituted triheterocyclic benzothiazole functionalities under solvent-free condition

Amol B. Atar · Yeon Tae Jeong

Received: 26 September 2013 / Accepted: 13 January 2014 / Published online: 7 February 2014 © Springer International Publishing Switzerland 2014

Abstract A series of diverse polyfunctionalized triheterocyclic benzothiazoles were easily prepared in excellent yields via the Biginelli reaction of 2-aminobenzothiazole with substituted benzaldehydes and α -methylene ketones using FeF₃ as an expeditious catalyst under solvent-free conditions. The protocol provides a practical and straightforward approach toward highly functionalized triheterocyclic benzothiazole derivatives in excellent yields. The reaction was conveniently promoted by FeF3 and the catalyst could be recovered easily after the reaction and reused without any loss of its catalytic activity. The advantageous features of this methodology are high atom economy, operational simplicity, shorter reaction time, convergence, and facile automation.

Keywords $4H$ -pyrimido[2, 1-*b*]benzothiazoles \cdot Iron (III) fluoride · Multicomponent reaction · Solvent free · MCRs

Introduction

Substituted benzothiazoles have received considerable attention in the field of synthetic organic chemistry due to their numerous applications in the pharmaceutical industry. Functionalized benzothiazoles have shown anticonvulsant [\[1](#page-11-0)], antitumor [\[2\]](#page-11-1), antiinflammatory [\[3](#page-11-2)], and antitubercular [\[4\]](#page-11-3) activities, and also act as chemosensitizers in chemotherapy and neuroprotectant-cerebral antischemic agents [\[5](#page-11-4)[–7](#page-11-5)].

Electronic supplementary material The online version of this article (doi[:10.1007/s11030-014-9506-x\)](http://dx.doi.org/10.1007/s11030-014-9506-x) contains supplementary material, which is available to authorized users.

A. B. Atar \cdot Y. T. Jeong (\boxtimes)

Department of Image Science and Engineering, Pukyong National University, Busan 608-737, Republic of Korea e-mail: ytjeong@pknu.ac.kr

Furthermore, they are also extensively used in material science. The industrial applications such as antioxidants [\[8](#page-11-6)], vulcanization accelerators [\[9](#page-11-7)], and a dopant in light emitting organic electroluminescent devices [\[10\]](#page-11-8) have also been reported. The important of chemical and pharmacological properties of benzothiazoles derivatives and the development of synthetic methods which enable a facile access to these heterocyclic compounds are desirable. Recently, many efforts have been devoted to develop novel and highly efficient synthetic protocols for the synthesis of functionalized benzothiazoles such as multicomponent coupling reactions, transition metal catalyzed cyclizations, and [3+2] cycloadditions [\[11](#page-11-9)[–18\]](#page-12-0). In the midst of them, multicomponent coupling reactions (MCRs) are known as a powerful tool for the construction of novel and structurally complex molecules in a single pot ensuring high atom economy, good overall yields and high selectivity, lower costs, shorter reaction times, minimizing waste, labor, energy, and avoidance of expensive purification processes [\[19](#page-12-1)– [21](#page-12-2)].

The best-known multicomponent reaction for 4*H*pyrimido[2,1-*b*]benzothiazoles and related polyheterocycles is the Biginelli reaction [\[22](#page-12-3)[–24\]](#page-12-4). The simple and straightforward procedure reported by Biginelli [\[25\]](#page-12-5) in 1893 involves a three-component condensation reaction of β-ketoesters, arylaldehydes, and urea to give 3,4-dihydropyrimidin-2- (1*H*)one in one-pot procedure. The urea has been reported as 2-aminobenzimidazoles and 2-aminobenzothioazoles derivatives as alternates [\[26](#page-12-6)[–28\]](#page-12-7). The Biginelli reaction can be promoted by acid or base catalysis or by heating. Very recently, catalysts such as $AICI_3$ [\[29](#page-12-8)], TBAHS [\[30](#page-12-9)], hydrotalcite [\[31\]](#page-12-10), and *N*,*N*-dichlorobis(2,4,6-trichlorophenyl) urea [\[32](#page-12-11)] have been shown to be effective for the synthesis of 4*H*-pyrimido[2,1-*b*]benzothiazoles. Although these methods provide good results in many instances, there is still a great

Scheme 1 Synthesis of fully substituted triheterocyclic benzothiazole functionalities catalyzed by FeF3 under solvent-free condition

demand for rapid and environment-friendly catalytic reaction conditions. We decided to find out the best environmentfriendly catalytic system for this one-pot Biginelli reaction.

It is reported that $FeF₃$ is an efficient and inexpensive catalyst for the synthesis of polyhydroquinoline derivatives via unsymmetrical Hantzsch reaction [\[33\]](#page-12-12). We tested the threecomponent reaction of 2-aminobenzothiazole with substituted benzaldehydes and α-methylene ketones using $FeF₃$ as an expeditious catalyst under solvent-free conditions. We found FeF_3 to be an effective catalyst for the synthesis of triheterocyclic 4*H*-pyrimido[2,1-*b*]benzothiazole derivatives in good to excellent yields and short reaction times. Based on our previous endeavors in exploring novel and practical multicomponent reactions to synthesize useful heterocyclic compounds [\[34](#page-12-13)[–37\]](#page-12-14), we proceeded to investigate the potential use of FeF₃ as a catalyst for the synthesis of $4H$ -pyrimido[2,1*b*]benzothiazoles. So herein we wish to report a tandem synthesis of 4*H*-pyrimido[2,1-*b*]benzothiazole derivatives by using FeF₃ as expeditious reusable catalyst in an excellent yield (Scheme [1\)](#page-1-0).

Results and discussion

In order to optimize the reaction conditions, 2-aminobenzothiazole, 4-chlorobenzaldehyde, and methyl acetoacetate were taken as model reactants in the presence of different catalyst and solvent (Table [1\)](#page-2-0). In order to establish the effectiveness of the catalyst for the synthesis of 4*H*pyrimido[2,1-*b*]benzothiazole derivatives, a test reaction was performed without catalyst using 2-aminobenzothiazole, 4 chlorobenzaldehyde, and methyl acetoacetate in ethanol at reflux. It was found that only a trace amount of product was obtained in the absence of catalyst even after 10 h (Table [1,](#page-2-0) entry 1). In order to develop a viable approach, the model reaction was investigated using different catalysts including $CaCl₂$, $SiO₂$, $FeCl₃$, $Zn(OTf)₂$, $ZnCl_2$, CuCl₂, FeF₃, Li(OTf), SnCl₂. 2H₂O, and CuF₂. Among all screened catalyst, $FeF₃$ gave the best result in view of yield and reaction time (Table [1,](#page-2-0) entry 8). In contrast CaCl₂, SiO₂, Zn(OTf)₂, ZnCl₂, Li(OTf), and SnCl₂. 2H₂O did not afford the desired product in good yields (Table [1,](#page-2-0) entries 2, 3, 5, 6, 10, and 11). Fe F_3 was shown to be more effective than $CuF₂$ in terms of yield and time for completion of the reaction (Table [1,](#page-2-0) entries 8 and 13).

To assess the effect of solvents on this reaction, we screened different solvents such as toluene, EtOH, acetonitrile, DMF, ethylene glycol, methanol, water, and THF. It was observed that under solvent condition required longer times (2–4 h) to afford comparable yields (Table [1,](#page-2-0) entries 14–20). When the reaction was performed under solvent-free conditions, high yield of target product was obtained (Table [1,](#page-2-0) entry 8). Moreover, we found that the yields were affected by the amount of FeF₃ loaded. When 5, 10, and 20 mol% of FeF₃ were used, the yields were 90, 98, and 95 $\%$, respectively (Table [1,](#page-2-0) entries 8, 21, and 22). Therefore, 10 mol% of FeF3 was sufficient and optimal quantity for the completion of the reaction.

To explore the scope and limitations of this reaction further, we extended our studies to the use of various substituted aryl/aliphatic aldehydes and α -methylene ketones in the presence of 2-aminobenzothiazole. It was gratifying to observe that most of the tested substrates exhibited satisfactory reactivity profiles, in all cases leading to a heterocyclization sequence that readily afforded the target structures (Table [2\)](#page-3-0). Compared with aromatic aldehydes, aliphatic aldehyde afforded relatively lower yields of the corresponding 4*H*-pyrimido[2,1-*b*]benzothiazole. A variety of α -methylene ketones like various substituted acetoacetates, 1,3 diketones, as well as isopropyl acetoactate reacted with 2-aminobenzothiazole and aldehydes under optimized conditions.

The reusability of the FeF₃ catalyst is one of the most important benefits and makes it useful for commercial applications as well. Thus, the recovery and reusability of the catalyst were investigated. The recyclability of the catalyst was checked with model reaction (Table [3,](#page-8-0) entries 1–4). The catalyst was recovered after completion of the first fresh run, the reaction mixture cooled to room temperature, and then water was added. The catalyst was dissolved in water and product was precipitated out. The precipitated crude product was separated by simple filtration and FeF3was recovered by evaporating the aqueous layer under reduced pressure. The recovered FeF₃ (10 mol%) was dried at 90–100 °C for 12 h and tested in up to three more reaction cycles. The same catalyst (10 mol%) was reused for subsequent reactions (three runs) with fresh substrates under the same conditions. The catalyst showed excellent recyclability in all these reactions (Table [3\)](#page-8-0), as the reaction times and yield remained almost the same without having a loss of catalytic activity.

Table 1 Optimization of catalysts, solvents, and temperature in the synthesis of **4aa**

Reaction conditions: 4-Cl benzaldehyde (1 mmol), methyl acetoacetate (1 mmol), 2-aminobenzothiazole (1 mmol), catalyst (10 % mol) *^a* Isolated yield

Conclusion

In summary, we have described an efficient and environmentally benign protocol for the synthesis of fully substituted triheterocyclic benzothiazole functionalities via Biginelli reaction of 2-aminobenzothiazole with diversified α -methylene ketones and aldehydes using iron fluoride as a recyclable catalyst. The main advantages of this present methodology are the simple work up, easy recovery of catalyst, no need for anhydrous conditions, no base, or any additional activator required.

Experimental

Chemicals were purchased from Aldrich and Alfa Aesar chemical companies and used as it is. The NMR spectra were recorded in CDCl₃ on a Jeol JNM ECP 400 NMR instrument using TMS as an internal standard. The HRMS was recorded on a Jeol JMS-700 mass spectrometer. Melting points were taken in open capillaries on an Electrothermal-9100 instrument (Japan).

General procedure for the synthesis of fully substituted triheterocyclic benzothiazole functionalities (Table [2\)](#page-3-0)

A mixture of aldehydes (1 mmol), α-methylene ketone (1 mmol), and 2-aminobenzothiazole (1 mmol) was heated at 80 ◦C under solvent-free conditions using iron flouride as a catalyst (10 mol%). The reaction was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to room temperature, and the residue was diluted

| Entry | $\label{thm:thydes} \text{Aldehydes}$ | α -Methylene ketone | $\bf Product$ | Time | Yield ^a | MP (°C) | ${\bf References}$ |
|----------------|--|---------------------------------------|-----------------------------------|-----------|--------------------|-------------|--------------------|
| | | | | (\hbar) | $(\%)$ | | |
| $\,1$ | O_{max} H CI | ဂူ | CI O S | $0.5\,$ | 98 | $179 - 180$ | |
| $\sqrt{2}$ | 2a $O_{\text{max}}H$ 2 _b | 3a Ο O | 4aa Ο s | $\,1\,$ | 95 | $153 - 154$ | |
| $\sqrt{3}$ | $O_{\text{max}}H$ CI | 3 _b \overline{O} O | 4bb CI | $0.7\,$ | 96 | $132 - 133$ | |
| $\overline{4}$ | 2a $O_{\text{max}}H$ ĊI 2a | 3c О O Ο 3d | 4ac CI Ο n 4ad | $0.5\,$ | $\ensuremath{97}$ | $83 - 84$ | |
| $\sqrt{5}$ | O_{N} \sim H CI 2a | O O 3e | CI. O O =N 4ae | $1.5\,$ | 93 | $112 - 113$ | $\qquad \qquad -$ |
| $\sqrt{6}$ | $O_{\text{max}}H$ CI 2a | $\ddot{\mathbf{O}}$ О 3f | CI 4af | $\,1$ | 92 | $127 - 128$ | |

Table 2 Synthesis of triheterocyclic benzothiazole functionalities catalyzed by FeF3

Table 2 continued

Table 2 continued

Table 2 continued

Entry Aldehydes α-Methylene ketone Product Time (h) Yield^a (%) MP (°C) References 24 $O_{\!\!\infty}$ H **Cl 2e O O O 3b S N N O O Cl 4eb** 0.5 94 125–127 30 25 $O_{\text{c}}H$ **Cl 2a O O O 3b S N N O O Cl 4ab** 0.5 93 142–143 – 26 O_{c} H **OH 2n O O O 3b S N N O O HO 4nb** 1.5 88 209–210 31 27 $O_{\text{c}}H$ $NO₂$ **2o O O O 3b S N N O O O2N 4ob** 2 85 155–156 30 28 O_{\diamondsuit} H **O MeO**

Table 2 continued

2p 3b 4pb 1.5 86 140–141 30 Reaction conditions: aldehyde (1 mmol), α -methylene ketone (1 mmol), 2-aminobenzothiazole (1 mmol), catalyst (10 mol%), solvent-free conditions, 80 °C

S N N **O**

^a Isolated yield

OMe

O O

O

Table 3 Recycling and reuse of FeF₃

| Entry | Reaction cycle | Yield ^a $(\%)$ | |
|-------|-------------------|---------------------------|--|
| | First (fresh run) | 98 | |
| | Second cycle | 96 | |
| | Third cycle | 95 | |
| | Fourth cycle | 95 | |

^a Isolated yield

with water. The mixture was filtered and washed with water. The FeF3 catalyst was dissolved in water and also recovered by evaporating the aqueous layer under reduced pressure. The solid crude product was easily purified by column chromatography over silica gel using hexane and ethyl acetate to get pure product **4**.

*Methyl-2-methyl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4aa***)*

Pale yellow solid, m.p. 179–180 °C; Yield 98 %. ¹H NMR (400 MHz, CDCl₃): δ 7.43 (dd, $J_1 = 8$ Hz, $J_2 =$ 1.84 Hz, 1H), 7.37–7.34 (m, 2H), 7.24–7.20 (m, 3H), 7.14– 7.10 (m, 1H), 7.04 (d, 8 Hz, 1H), 6.37 (s, 1H), 3.71 (s, 3H), 2.44 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 167.94, 164.57, 156.35, 140.96, 138.84, 135.24, 129.98, 129.49, 127.76, 125.20, 124.87, 123.94, 112.66, 103.65, 85.17, 52.26, 24.88 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15ClN2O2S (*m*/*z*) 370.0543. Found: 370.0543.

*Ethyl-2-methyl-4-(4-methylphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4bb***)*

Brown solid, m.p. 153–154 ◦C; Yield 95 %. 1H NMR (400 MHz, CDCl₃): δ 7.38 (d, 8 Hz, 1 H), 7.31 (d, 8 Hz, 2H), 7.25–7.17 (m, 1H), 7.10–7.03 (m, 4H), 6.35 (s, 1H), 4.18–4.13 (m, 2H), 2.47 (s, 3H), 2.22 (s, 3H), 1.28 (t, 12 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): ^δ 166.49, 163.35, 154.34, 154.31, 138.47, 138.10, 137.94, 129.98, 129.26, 128.98, 127.09, 126.54, 123.87, 123.81, 122.06, 111.77, 103.18, 60.02, 57.48, 23.42, 21.06, 14.33 ppm. HRMS (ESI, *m*/*z*): Calcd for C21H20N2O2S (*m*/*z*) 364.1245 Found: 364.1245.

*Isopropyl-2-methyl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ac***)*

Brown solid, m.p. 132–133 °C; Yield 96 %. ¹H NMR (400 MHz, CDCl3): δ 7.43–7.35 (m, 3H), 7.23–7.19 (m, 3H), 7.13–7.09 (m, 1H), 7.04 (d, 8Hz, 1H), 6.35 (s, 1H), 5.06–5.03 (m, 1H), 2.45 (s, 3H), 1.28 (d, 8 Hz, 3H), 1.21 (d, 8 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): ^δ 165.88, 163.20, 154.74, 139.86, 137.77, 134.08, 128.75, 128.60,

126.59, 124.02, 123.73, 122.21, 111.52, 102.99, 67.62, 57.10, 23.75, 22.19, 21.97 ppm. HRMS (ESI, *m*/*z*): Calcd for C21H19ClN2O2S (*m*/*z*) 398.0856 Found: 398.0856.

*Ethyl-2-phenyl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ad***)*

Yellow solid, m.p. 83–84 $°C$: Yield 97 %. ¹H NMR (400 MHz, CDCl3): δ 7.49–7.47 (m, 3H), 7.39–7.33 (m, 5H), 7.29–7.25 (m, 3H), 7.19–7.15 (m, 1H), 7.10 (d, 8 Hz, 1H), 6.50 (s, 1H), 3.89–3.86 (m, 2H), 0.82 (t, 12 Hz, 3H) ppm. 13 C NMR(100 MHz, CDCl₃): δ 166.69, 163.42, 155.04, 140.56, 139.80, 137.69, 134.34, 129.07, 128.44, 128.38, 128.13, 127.70, 126.78, 124.23, 124.14, 122.30, 111.69, 102.74, 60.07, 57.60, 13.50 ppm. HRMS (ESI, *m*/*z*): Calcd for C₂₅H₁₉ClN₂O₂S (*m*/*z*) 446.0856 Found: 446.0856.

*Ethyl-2-butyral-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ae***)*

Brown solid, m.p. 112–113 \degree C; Yield 93 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.41 (d, 8 Hz, 1H), 7.38–7.35 (m, 2H), 7.22–7.17 (m, 3H), 7.12–7.03 (m, 2H), 6.37 (s, 1H), 4.19–4.14 (m, 2H), 2.80–2.77 (m, 2H), 1.70–1.65 (m, 2H), 1.28 (t, 12 Hz, 3H), 0.99 (t, 12 Hz, 3H) ppm. ¹³C NMR(100 MHz, CDCl₃): δ 166.24, 163.45, 158.90, 140.02, 137.82, 134.09, 128.82, 128.53, 128.36, 126.74, 126.56, 123.95, 123.82, 122.18, 11.45, 102.65, 60.15, 57.09, 38.20, 22.06, 14.29 ppm. HRMS (ESI, *m*/*z*): Calcd for C22H21ClN2O2S (*m*/*z*) 412.1012 Found: 412.1012.

*Ethyl-2-4-isobutyryl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4af***)*

Brown solid, m.p. 127–128 ◦C; Yield 92 %. 1H NMR (400 MHz, CDCl3): δ 7.41 (d, 8 Hz, 1H), 7.37–7.30 (m, 2H), 7.22–7.18 (m, 3 H), 7.13–7.07 (m, 1H), 7.03 (d, 8 Hz, 1H), 6.34 (s, 1 H), 4.19–4.14 (m, 2H), 3.97–3.93 (m, 1H), 1.29–1.20 (m, 6H), 1.13 (t, 12Hz, 3H) ppm. ¹³C NMR(100 MHz, CDCl₃): δ 166.28, 163.62, 163.34, 140.21, 137.87, 134.04, 129.41, 129.06, 128.81, 128.49, 126.44, 123.95, 123.78, 122.15, 111.24, 101.38, 60.08, 57.08, 30.67, 20.49, 20.37, 14.29ppm. HRMS (ESI, *m*/*z*): Calcd for $C_{22}H_{21}CIN_2O_2S$ (m/z) 412.1012 Found: 412.1012.

*Ethyl-2-4-chloro-4-(4-chlorophenyl)-4Hpyrimido[2,1-b][1,3]benzothiazole-3-carboxylate (***4ag***)*

Brown solid, m.p. 135–136 ◦C; Yield 90 %. 1H NMR (400 MHz, CDCl₃): δ 7.45 (dd, $J_1 = 4Hz$, $J_2 = 8Hz$, 1H), 7.39-7.36 (m, 2H), 7.31 (s, 1H), 7.25–7.21 (m, 2H), 7.17– 7.13 (m, 1H), 7.07 (d, 8 Hz, 1H), 6.41 (s, 1H), 4.74–4.70 $(m, 2H)$, 4.23–4.18 $(m, 2H)$, 1.30 $(t, 12 Hz, 3H)$ ppm. ¹³C NMR (100 MHz, CDCl3): δ 165.00, 164.37, 139.13, 137.41, 134.57, 129.77, 129.53, 129.02, 128.61, 128.43, 126.79, 126.35, 125.11, 124.38, 124.01, 122.35, 111.67, 104.17, 60.83, 57.14, 44.58, 14.20ppm. HRMS (ESI, *m*/*z*): Calcd for $C_{20}H_{16}Cl_2N_2O_2S$ (m/z) 418.031 Found: 418.031.

*Ethyl-2-4-trifluoro-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ah***)*

Pale yellow solid, m.p. 143–144 $°C$; Yield 88 %. ¹H NMR (400 MHz, CDCl₃): δ 7.49 (dd, $J_1 = 4Hz$, $J_2 = 8Hz$, 1H), 7.35–7.32 (m, 2H), 7.28–7.17 (m, 4H), 7.07 (d, 8 Hz, 1H), 6.43 (s, 1H), 4.20–4.15 (m, 2H), 1.23 (t, 12 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.89, 163.66, 137.85, 136.99, 135.18, 129.74, 129.39, 128.27, 127.38, 127.02, 124.76, 124.07, 122.45 ppm. HRMS (ESI, *m*/*z*): Calcd for C20H14ClF3N2O2S (*m*/*z*) 438.0417 Found: 438.0417.

*2-Methyl-4-(4-fluorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-ethanone (***4ci***)*

Brown solid, m.p. 122–123 ◦C; Yield 93 %. 1H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.46–7.38 (m, 3H), 7.24 (d, 8 Hz, 1H), 7.16–7.7.07 (m, 2H), 6.92–6.87 (m, 2H), 6.55 (s, 1H), 2.45 (s, 3H), 2.40 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 195.28, 163.69, 154.56, 137.89, 137.19, 128.88, 128.80, 126.85, 125.95, 125.95, 124.24, 123.90, 122.15, 115.61, 115.40, 114.18, 111.94, 56.24, 31.92, 25.19 ppm. HRMS $(ESI, m/z):$ Calcd for $C_{19}H_{15}FN_{2}OS(m/z)$ 338.0889 Found: 338.0889.

*T-Butyl-2-4-methyl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4aj***)*

Brown solid, m.p. 102–103 °C; Yield 90 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.42 (dd, $J_1 = 4\text{ Hz}, J_2 = 8Hz, 1H$), 7.36–7.34 (m, 2H), 7.24–7.20 (m, 3H), 7.13–7.09 (m, 1H), 7.03 (d, 8 Hz, 1H), 6.33 (s, 1H), 2.41 (s, 3H), 1.46 (s, 9H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 165.79, 162.86, 153.67, 139.83, 137.85, 134.03, 128.75, 128.48, 126.55, 123.93, 123.76, 122.20, 111.42, 104.23, 80.69, 57.09, 28.40, 23.69 ppm. HRMS (ESI, m/z): Calcd for C₂₂H₂₁ClN₂O₂S (*m*/*z*) 412.1012 Found: 412.1012.

*Ethyl-2-4-nitrophenyl-4-(4-chlorophenyl)-4Hpyrimido[2,1-b][1,3]benzothiazole-3-carboxylate (***4ak***)*

Orange solid, m.p. 198–199 °C; Yield 90 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 8.23–8.20 (m, 2H), 7.56–7.47 (m, 5H), 7.32–7.13 (m, 5H), 6.56 (s, 1H), 3.92–3.90 (m, 2H), 0.89 (t, 10 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 165.54, 164.02, 153.02, 147.54, 147.42, 139.43, 137.45, 134.65, 129.29, 129.22, 128.88, 128.40, 128.05, 127.04, 124.63, 124.06, 123.89, 122.97, 122.44, 111.94, 103.51, 60.42, 57.51, 13.66 ppm. HRMS (ESI, *m*/*z*): Calcd for *C*25H18ClN3O4S (*m*/*z*) 491.0707 Found: 491.0707.

*Methyl-2-methyl-4-(4-isopropylphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4da***)*

Brown solid, m.p. 146–147 °C; Yield 93 %. ¹H NMR (400 MHz, CDCl3): δ 7.42 (d, 8 Hz, 1H), 7.32 (d, 8 Hz, 1H), 7.26–7.20 (m, 1H), 7.13–7.08 (m, 4H), 6.36 (s, 1H), 3.71 (s, 3H), 2.82–2.76 (m, 1H), 2.44 (s, 3H), 1.16 (d, 8 Hz, 6H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 168.16, 164.57, 155.96, 149.96, 139.86, 139.20, 128.01, 127.82, 127.67, 124.92, 123.17, 112.87, 104.07, 58.45, 52.17, 34.79, 24.86, 24.76 ppm. HRMS (ESI, m/z): Calcd for $C_{22}H_{22}N_2O_2S$ (*m*/*z*) 378.1402 Found: 378.1402.

*Methyl-2-methyl-4-(2-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ea***)*

Yellow solid, m.p. 153–154 ◦C; Yield 93 %. Mp 153–154 ◦C. ¹H NMR (400 MHz, CDCl₃): δ 7.61 (dd, J₁ = 4Hz, J₂ = 8Hz, 1H), 7.43 (d, 8 Hz, 1H), 7.38 (d, 8 Hz, 1H), 7.28– 7.22 (m, 2H), 7.19–7.09 (m, 3H), 6.75 (s, 1H), 3.67 (s, 3H), 2.48 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 166.58, 163.47, 155.59, 139.67, 138.16, 131.45, 130.25, 129.65, 129.45, 128.16, 126.80, 124.09, 123.26, 121.99, 111.60, 102.47, 54.36, 50.97, 23.53 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15ClN2O2S (*m*/*z*) 370.0543 Found: 370.0543.

*Methyl-2-methyl-4-(4-methylphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ba)**

Brown solid, m.p. 154–155 °C; Yield 90 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta$ 7.41–7.39 (m, 1H), 7.30 (d, 8 Hz, 2H), 7.22–7.18 (m, 1H), 7.11–7.04 (m, 4H), 6.35 (s, 1H), 3.69 (s, 3H), 2.44 (s, 3H), 2.23 (s, 3H) ppm. 13C NMR (100 MHz, CDCl₃): δ 168.11, 164.55, 155.95, 139.65, 139.21, 139.15, 130.44, 128.05, 127.66, 124.95, 124.90, 123.18, 112.83, 104.08, 58.53, 52.15, 24.80, 22.19 ppm. HRMS (ESI, *m*/*z*): Calcd for C20H18N2O2S (*m*/*z*) 350.1089 Found: 350.1089.

*Methyl-2-methyl-4-(2-fluorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4fa***)*

Yellow solid, m.p. 139–140 $°C$; Yield 88 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.52–7.48 (m, 1H), 7.39 (d, 8 Hz, 1H), 7.25–7.22 (m, 2H), 7.20–7.09 (m, 2H), 7.06–6.95 (m, 2H), 6.67 (s, 1H), 3.67 (s, 3H), 2.49 (s, 3H) ppm. 13 C

NMR (100 MHz, CDCl₃): δ 167.67, 164.49, 160.88, 158.40, 157.06, 139.02, 130.84, 130.81, 127.92, 126.27, 126.23, 125.18, 124.62, 123.18, 116.39, 116.16, 112.11, 112.06, 102.85, 52.19, 51.85, 24.65 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15FN2O2S (*m*/*z*) 354.0838 Found: 354.0838.

*Methyl-2-methyl-4-(4-fluorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ca***)*

Yellow solid, m.p. 160–161 °C; Yield 91 %. ¹H NMR (400 MHz, CDCl3): δ 7.44–7.37 (m, 3H), 7.25–7.20 (m, 1H), 7.14–7.05(m, 2H), 6.95–6.90 (m, 2H), 6.38 (s, 1H), 3.71 (s, 3H), 2.45 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 166.92, 163.66, 155.10, 137.80, 137.34, 128.84, 128.76, 126.63, 124.05, 123.80, 122.23, 115.72, 115.51, 111.62, 102.80, 57.00, 51.16, 23.76 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15FN2O2S (*m*/*z*) 354.0838 Found: 354.0838.

*Methyl-2-methyl-4-(4-bromophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ga***)*

Yellow solid, m.p. 166–167 °C; Yield 96 %. ¹H NMR (400 MHz, CDCl3): δ 7.42 (d, 8 Hz, 1H), 7.37 (d, 8Hz, 2H), 7.30–7.27 (m, 2H), 7.22 (t, 12 Hz, 1H), 7.12 (t, 12 Hz, 1H), 7.03 (d, 8 Hz, 1H), 6.35 (s, 1H), 3.71 (s, 3H), 2.44 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 166.79, 163.44, 155.25, 140.33, 137.68, 131.81, 128.68, 126.65, 124.08, 123.72, 122.33, 122.22, 111.53, 102.44, 57.10, 51.16, 23.77 ppm. HRMS (ESI, m/z): Calcd for C₁₉H₁₅BrN₂O₂S (m/z) 414.0038 Found: 414.0038.

*Methyl-2-methyl-4-(2-chloro-6-fluorophenyl)-4Hpyrimido[2,1-b][1,3]benzothiazole-3-carboxylate (***4ha***)*

Orange solid, m.p. 148–149 °C; Yield 85 %. ¹H NMR $(400 \text{ MHz}, \text{CDC1}_3)$: δ 7.40 (dd, $J_1 = 2\text{ Hz}, J_2 = 8\text{ Hz}, 1\text{ H}$), 7.22–7.7.09 (m, 6H), 6.99 (s, 1H), 3.65 (s, 3H), 2.44 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 167.73, 164.42, 157.97, 139.23, 131.22, 131.12, 127.85, 125.07, 124.30, 123.14, 112.05, 51.93, 24.84 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15BrN2O2S (*m*/*z*) 388.0449 Found: 388.0449.

*Methyl-2-methyl-4-(2-methoxyphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ia***)*

Yellow solid, m.p. 145–146 $°C$; Yield 89 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.47 (dd, $J_1 = 2\text{ Hz}, J_2 = 8\text{ Hz}, 1\text{ H}$), 7.35–7.7.31 (m, 2H), 7.20–7.13 (m, 2H), 7.07–7.03 (m, 1H), 6.87–6.80 (m, 2H), 6.71 (s, 1H), 3.91 (s, 3H), 3.63 (s, 3H), 2.46 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.00, 164.38, 156.99, 156.23, 139.47, 130.86, 130.79, 130.68, 127.44, 124.61, 124.35, 122.75, 122.13, 103.09,

56.66, 53.24, 51.85, 24.50 ppm. HRMS (ESI, *m*/*z*): Calcd for C20H18N2O3S (*m*/*z*) 366.1038 Found: 366.1038.

*Methyl-2-methyl-4-(3,4,5-methoxyphenyl)-4Hpyrimido[2,1-b][1,3]benzothiazole-3-carboxylate (***4ja***)*

Brown solid, m.p. 138–139 °C; Yield 87 %.¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta$ 7.46 (dd, $J_1 = 2\text{ Hz}, J_2 = 8\text{ Hz}, 1\text{ H}$), 7.28–7.23 (m, 1H), 7.17–7.10 (m, 2H), 6.60 (s, 2H), 6.36 $(s, 1H)$, 3.76 (t, 12 Hz, 12H), 2.44 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 167.08, 153.32, 136.97, 126.67, 124.05, 124.05, 123.72, 122.19, 111.80, 103.97, 102.81, 60.71, 57.70, 56.13, 51.13, 23.72 ppm. HRMS (ESI, *m*/*z*): Calcd for C22H22N2O5S (*m*/*z*) 426.1249 Found: 426.1249.

*Methyl-2-methyl-4-(3-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ka***)*

Yellow solid, m.p. 139–140 $°C$; Yield 95 %. ¹H NMR (400 MHz, CDCl3): δ 7.45–7.40 (m, 2H), 7.30–7.11 (m, 5H), 7.05 (d, 8 Hz, 1H), 6.37 (s, 1H), 3.72 (s, 3H), 2.45 (s, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 167.87, 164.59, 156.52, 144.31, 138.80, 135.73, 131.04, 129.69, 128.21, 127.82, 126.30, 125.23, 124.87, 123.36, 112.64, 103.42, 58.32, 52.28, 24.89 ppm. HRMS (ESI, *m*/*z*): Calcd for C19H15ClN2O2S(*m*/*z*) 370.0543 Found: 370.0543.

*Methyl-2-methyl-4-(butyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4la***)*

Brown solid, m.p. 123–124 \degree C; Yield 85 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta = 7.48 \text{ (t, 8Hz, 1H)}, 7.38-7.33 \text{ (m,$ 1H), 7.20 (d, 8Hz, 2H), 5.59 (t, 8Hz, 1H), 3.78 (s, 3H), 2.41 (s, 3H), 1.80–1.77(m, 1H), 1.55–1.52 (m, 1H), 1.40–1.36 (m, 1H), 1.12–1.07 (m, 1H), 0.79–0.78(m, 3H) ppm. 13C NMR $(100 \text{ MHz}, \text{CDCl}_3): \delta = 167.27, 164.16, 157.35, 137.98,$ 126.65, 124.04, 123.78, 122.36, 111.02, 100.06, 53.22, 51.13, 36.19, 23.45, 16.80, 13.97 ppm. HRMS (ESI, *m*/*z*): Calcd for C16H18N2O2S (*m*/*z*) 302.1089 Found 302.1089

*Methyl-2-methyl-4-(propyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ma***)*

Brown solid, m.p. 120–121 \degree C; Yield 88 %.¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta = 7.47 \text{ (d, 8Hz, 1H)}, 7.36-7.33 \text{ (m,$ 1H), 7.18 (t, 8Hz, 2H), 5.61 (t, 8Hz, 1H), 3.78 (s, 3H), 2.42 (s, 3H), 1.89–1.87(m, 1H), 1.63–1.61 (m, 1H), 0.79(t, 12Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): $\delta = 167.25$, 164.29, 157.55, 137.96, 126.62, 123.98, 123.78, 122.35, 111.05, 99.36, 54.07, 51.12, 26.56, 23.47, 7.69 ppm. HRMS (ESI, *m*/*z*): Calcd for C15H16N2O2S (*m*/*z*) 288.0932 Found 288.0932.

*Ethyl-2-methyl-4-(2-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4eb***)*

Yellow solid, m.p. 125–127 $°C$; Yield 94 %. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.62 (dd, $J_1 = 4\text{ Hz}, J_2 = 8\text{ Hz}, 1\text{ H}$), 7.47 (d, 8 Hz, 1H), 7.38 (d, 8 Hz, 1H), 7.27–7.23 (m, 2H), 7.19–7.09 (m, 3H), 6.76 (s, 1H), 4.17–4.13 (m, 2H), 2.49 (s, 3H), 1.24 (t, 12 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 166.22, 163.33, 155.31, 139.58, 138.23, 131.46, 130.45, 129.68, 129.45, 128.08, 126.74, 124.04, 123.26, 121.98, 111.67, 102.77, 59.99, 54.46, 23.66, 14.42 ppm. HRMS (ESI, m/z): Calcd for $C_{20}H_{17}CIN_2O_2S$ (*m*/*z*) 384.0699 Found 384.0699.

*Ethyl-2-methyl-4-(4-chlorophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ab***)*

Brown solid, m.p. 142–143 $°C$; Yield 93 %.¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.42–7.35 (m, 3H), 7.21–7.17 (m, 3H), 7.10–7.02 (m, 2H), 6.36 (s, 1H), 4.19–4.14 (m, 2H), 2.46 (s, 3H), 1.28 (t, 12 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 166.31, 163.28, 154.90, 139.83, 137.07, 134.07, 128.77, 128.50, 126.59, 124.03, 123.70, 122.18, 111.53, 102.69, 60.13, 57.06, 23.70, 14.34 ppm. HRMS (ESI, m/z): Calcd for C₂₀H₁₇ClN₂O₂S (m/z) 384.0699 Found 384.0699.

*Ethyl-2-methyl-4-(4-hydroxyphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4nb***)*

White solid, m.p. 209–210 \degree C; Yield 88 %.¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 9.31 (s, 1H), 7.56–7.32 (m, 4H), 7.22– 7.01 (m, 2H), 6.89–6.72 (m, 2H), 6.32 (s, 1H), 4.08– 4.14 (m, 2H), 2.49 (s, 3H), 1.26 (t, 12Hz, 3H) ppm. 13C NMR (100 MHz, CDCl₃): δ 165.21, 163.24, 156.31, 153.58, 136.49, 132.65, 128.87, 126.38, 123.42, 122.85, 122.21, 116.01, 111.85, 102.36, 59.45, 56.21, 23.11, 14.32 ppm. HRMS (ESI, m/z): Calcd for C₂₀H₁₈N₂O₃S (m/z) 366.1038 Found 366.1038.

*Ethyl-2-methyl-4-(4-nitrophenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4ob***)*

Pale yellow solid, m.p. 155–156 $°C$; Yield 85 %.¹H NMR (400 MHz, CDCl3): δ 7.65–7.32 (m, 4H), 7.21–7.05 (m, 4H), 6.42 (s, 1H), 4.25–4.15 (m, 2H), 2.46 (s, 3H), 1.30 (t, 12Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl₃): δ 165.21, 163.45, 155.86, 148.23, 147.56, 137.69, 128.32, 126.19, 124.67, 123.89, 122.89, 122.01, 112.14, 102.09, 59.49, 57.23, 23.43, 14.66 ppm. HRMS (ESI, *m*/*z*): Calcd for C20H17N3O4S (*m*/*z*) 395.0940 Found 395.0940.

*Ethyl-2-methyl-4-(4-methoxyphenyl)-4H-pyrimido[2,1 b][1,3]benzothiazole-3-carboxylate (***4pb***)*

Yellow solid, m.p. 140–141 $°C$; Yield 86 %.¹H NMR $(400 \text{ MHz}, \text{CDCl}_3)$: δ 7.55–7.30 (m, 4H), 7.01–6.82 (m, 4H), 6.31 (s, 3H), 4.12–4.02 (m, 2H), 3.75 (s, 3H), 2.41 (s, 3H), 1.27 (t, 12Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 166.45, 163.28, 159.45, 153.87, 152.23, 138.69, 132.79, 128.31, 125.98, 123.47, 122.87, 122.06, 120.69, 118.92, 112.89, 103.56, 60.85, 58.36, 55.21, 23.45, 14.23 ppm. HRMS (ESI, m/z): Calcd for C₂₁H₂₀N₂O₃S (m/z) 380.1195 Found 380.1195.

References

- 1. Singh SP, Mishra RS, Parmar SS, Brumieve SJ (1975) Synthesis of 2-(4 arylthiosemicarbazidocarbonylthio) benzthiazoles and their monamine oxidase inhibitory and anticonvulsant properties. J Pharm Sci 64:1245–1247. doi[:10.1002/jps.2600640730](http://dx.doi.org/10.1002/jps.2600640730)
- 2. Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MFG (2001) Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4 aminophenyl) benzothiazoles. J Med Chem 44:1446–1455. doi[:10.](http://dx.doi.org/10.1021/jm001104n) [1021/jm001104n](http://dx.doi.org/10.1021/jm001104n)
- 3. Singh SP, Vaid PK (1986) Some new 2-(4-butyl-3,5 dimethylpyrazol-1-yl)-6-substituted benzothiazoles, were assessed for their anti-inflammatory activity. Indian J Chem 25B:288–291
- 4. Pande AV, Lokhande SR, Patel MR, Khadse BG (1982) Synthesis and study of 2-substituted alkyl or aryl, amino 6-methyl benzothiazoles as antituberculosis agents. Indian Drugs 19:342–345
- 5. Klusa V (1995) Cerebrocrast, neuroprotectant, cognition enhancer. Drugs Future 20:135–139
- 6. Boer R, Gekeler V (1995) Chemosensitizers in tumor therapy: New compounds promise better efficacy. Drugs Future 20:499
- 7. Bretzel RG, Bollen CC, Maeser E, Federlin KF (1993) Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 21:S53–S64
- 8. Choudhary S, Kini SG, Mubeen M (2013) Antioxidant activity of novel coumarin substituted benzothiazole derivatives. Der Pharma Chemica 5:213–222
- 9. Hopper RJ (1993) 2-(Isopropylsulfinyl)-benzothiazole as a delayed action thiazole accelerator. Rubber Chem Technol 66:623–633. doi[:10.5254/1.3538334](http://dx.doi.org/10.5254/1.3538334)
- 10. Zhang XH, Wong OY, Gao ZQ, Lee CS, Kwong HL, Wu SK (2001) A new blue-emitting benzothiazole derivative for organic electroluminescent devices. Mater Sci Eng B 85:182–185. doi[:10.1016/](http://dx.doi.org/10.1016/S0921-5107(01)00607-9) [S0921-5107\(01\)00607-9](http://dx.doi.org/10.1016/S0921-5107(01)00607-9)
- 11. Bastug G, Eviolitte C, Marko IE (2012) Functionalized orthoesters as powerful building blocks for the efficient preparation of heteroaromatic bicycles. Org Lett 14:3502–3505. doi[:10.1021/](http://dx.doi.org/10.1021/ol301472a) [ol301472a](http://dx.doi.org/10.1021/ol301472a)
- 12. Tale RH (2002) Novel synthesis of 2- arylbenzothiazoles mediated by ceric ammonium nitrate (CAN). Org Lett 4:1641–1642. doi[:10.](http://dx.doi.org/10.1021/ol020027i) [1021/ol020027i](http://dx.doi.org/10.1021/ol020027i)
- 13. Karle M, Knecht W, Xue Y (2012) Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV. Bioorg Med Chem Lett 22:4839–4843. doi[:10.1016/j.bmcl.2012.05.046](http://dx.doi.org/10.1016/j.bmcl.2012.05.046)
- 14. Noolvi MN, Patel HM, Kaur M (2012) Benzothiazoles: search for anticancer agents. Eur J Med Chem 54:447–462. doi[:10.1016/j.](http://dx.doi.org/10.1016/j.ejmech.2012.05.028) [ejmech.2012.05.028](http://dx.doi.org/10.1016/j.ejmech.2012.05.028)
- 15. Jaseer EA, Prasad DJC, Dandapat A, Sekar G (2010) An efficient copper(II)-catalyzed synthesis of benzothiazoles through

intramolecular coupling-cyclization of *N*-(2 chlorophenyl)benzothioamide. Tetrahedron Lett 51:5009–5012. doi[:10.1016/j.tetlet.2010.07.079](http://dx.doi.org/10.1016/j.tetlet.2010.07.079)

- 16. Xue WJ, Guo YQ, Gao FF, Li HZ, Wu AX (2013) A novel selfsequence reaction network involving a set of six reactions in one pot: the synthesis of substituted benzothiazoles from aromatic ketones and anilines. Org Lett 15:890–893. doi[:10.1021/ol400029t](http://dx.doi.org/10.1021/ol400029t)
- 17. Trapani G, Franco M, Latrofal A, Carotti A, Genchi G, Serra M, Biggio G, Liso G (1996) Synthesis and benzodiazepine receptor binding of some imidazoand pyrimido[2,1-*b*]benzothiazoles. Eur J Med Chem 31:575–587. doi[:10.1016/0223-5234\(96\)89553-5](http://dx.doi.org/10.1016/0223-5234(96)89553-5)
- 18. Sahu PK, Sahu PK, Gupta SK, Thavaselvam D, Agarwal DD (2012) Synthesis and evaluation of antimicrobial activity of 4*H*pyrimido[2,1-*b*]benzothiazole, pyrazole and benzylidene derivatives of curcumin. Eur J Med Chem 54:366–378. doi[:10.1016/j.](http://dx.doi.org/10.1016/j.ejmech.2012.05.020) [ejmech.2012.05.020](http://dx.doi.org/10.1016/j.ejmech.2012.05.020)
- 19. Zhu J (2003) Recent developments in the isonitrile-based multicomponent synthesis of heterocycles. Eur J Org Chem 7:1133– 1144. doi[:10.1002/ejoc.200390167](http://dx.doi.org/10.1002/ejoc.200390167)
- 20. Domling A (2006) Recent developments in isocyanide-based multicomponent reactions in applied chemistry. Chem Rev 106:17–89. doi[:10.1021/cr0505728](http://dx.doi.org/10.1021/cr0505728)
- 21. Mihovilovic MD, Tanetty P (2007) Metal-assisted multicomponent reactions involving carbon monoxide-towards heterocycle synthesis. Angew Chem Int Ed 46:3612–3615. doi[:10.1002/anie.](http://dx.doi.org/10.1002/anie.200604743) [200604743](http://dx.doi.org/10.1002/anie.200604743)
- 22. Chebanov VA, Gura KA, Desenko SM (2010) Aminoazoles as key reagents in multicomponent heterocyclizations. Top Heterocycl Chem 23:41–84. doi[:10.1007/7081_2009_21](http://dx.doi.org/10.1007/7081_2009_21)
- 23. Sedash YV, Gorobets NY, Chebanov VA, Konovalova IS, Shishkin OV, Desenko SM (2012) Dotting the is in three-component Biginelli-like condensations using 3-amino-1,2,4-triazole as a 1,3 binucleophile. RSC Adv 2:6719–6728. doi[:10.1039/C2RA20195J](http://dx.doi.org/10.1039/C2RA20195J)
- 24. Wan JP, Liu Y (2010) Synthesis of dihydropyrimidinones and thiones by multicomponent reactions: strategies beyond the classical Biginelli reaction. Synthesis 23:3943–3953. doi[:10.1055/](http://dx.doi.org/10.1055/s-0030-1258290) [s-0030-1258290](http://dx.doi.org/10.1055/s-0030-1258290)
- 25. Biginelli P (1893) Synthesis of 3,4-dihydropyrimidin-2(1*H*)-ones. Gazz Chim Ital 23:360–416
- 26. Builla AJ, Alajarin R, Jordon P, Vaquero JJ (1995) Synthesis of unsymmetrically substituted 1,4- dihydropyridines and analogous calcium antagonists by microwave heating. Synthesis 4:389–391. doi[:10.1055/s-1995-3933](http://dx.doi.org/10.1055/s-1995-3933)
- 27. Shaabani A, Rahmati A, Naderi S (2005) A novel one-pot threecomponent reaction: synthesis of triheterocyclic 4*H*-pyrimido[2,1 *b*]benzazoles ring systems. Bioorg Med Chem Lett 15:5553. doi[:10.1016/j.bmcl.2005.08.101](http://dx.doi.org/10.1016/j.bmcl.2005.08.101)
- 28. Tu S, Shao Q, Zhou D, Cao L, Shi F, Li C (2007) Microwave-assisted efficient synthesis of benzo[4,5]imidazo[1,2 *a*]-pyrimidine derivatives in water under catalyst-free conditions. J Heterocycl Chem 44:1401–1406. doi[:10.1002/jhet.5570440625](http://dx.doi.org/10.1002/jhet.5570440625)
- 29. Sahu PK, Sahu PK, Lal J, Thavaselvam D, Agarwal DD (2012) A facile green synthesis and in vitro antimicrobial activity 4*H*pyrimido[2,1-*b*][1,3]benzothiazole derivatives using aluminum trichloride under solvent free conditions. Med Chem Res 21:3826– 3834. doi[:10.1007/s00044-011-9908-6](http://dx.doi.org/10.1007/s00044-011-9908-6)
- 30. Nagarapu L, Gaikwad HK, Palem JD, Venkatesh R, Bantu R, Sridhar B (2013) Convenient approach for the one-pot, three-component synthesis of triheterocyclic 4H-pyrimido[2,1 b]benzothiazole derivatives using TBAHS. Synth Commun 43:93– 104. doi[:10.1080/00397911.2011.592624](http://dx.doi.org/10.1080/00397911.2011.592624)
- 31. Sahu PK, Sahu PK, Jain R, Yadava R, Agarwal DD (2012) Hydrotalcite: recyclable, novel heterogeneous catalyst for facile, environmentally benign and high yielding multi-component synthesis and mechanistic study under solvent free conditions. Catal Sci Technol 2:2465–2475. doi[:10.1039/c2cy20067h](http://dx.doi.org/10.1039/c2cy20067h)
- 32. Rao GBD, Acharya BN, Verma SK, Kaushik MP (2011) *N*,*N*-Dichlorobis(2,4,6-trichlorophenyl)urea (CC-2) as a new reagent for the synthesis of pyrimidone and pyrimidine derivatives via Biginelli reaction. Tetrahedron Lett 52:809–812. doi[:10.1016/j.tetlet.](http://dx.doi.org/10.1016/j.tetlet.2010.12.039) [2010.12.039](http://dx.doi.org/10.1016/j.tetlet.2010.12.039)
- 33. Surasani R, Kalita D, Rao AVD, Yarbagi K, Chandrasekhar KB (2012) FeF₃ as a novel catalyst for the synthesis of polyhydroquinoline derivatives via unsymmetrical Hantzsch reaction. J Fluorine Chem 135:91–96. doi[:10.1016/j.jfluchem.2011.09.005](http://dx.doi.org/10.1016/j.jfluchem.2011.09.005)
- 34. Atar AB, Jeong YT (2013) Silica supported tungstic acid (STA): an efficient catalyst for the synthesis of bis-spiro piperidine derivatives under milder condition. Tetrahedron Lett 54:1302–1306. doi[:10.](http://dx.doi.org/10.1016/j.tetlet.2012.12.105) [1016/j.tetlet.2012.12.105](http://dx.doi.org/10.1016/j.tetlet.2012.12.105)
- 35. Reddy MV, Reddy CS, Jeong YT (2012) Microwave-assisted, montmorillonite K-10 catalyzed three- component synthesis of 2*H*-indazolo[2,1-b]phthalazine-triones under solvent-free conditions. Tetrahedron 68:6820–6828. doi[:10.1016/j.tet.2012.06.045](http://dx.doi.org/10.1016/j.tet.2012.06.045)
- 36. Atar AB, Dindulkar SD, Jeong YT (2013) Lithium triflate (LiOTf): a highly efficient and reusable catalytic system for the synthesis of diversified quinolines under neat conditions. Monatsh Chem 144:695–701. doi[:10.1007/s00706-012-0906-2](http://dx.doi.org/10.1007/s00706-012-0906-2)
- 37. Dindulkar SD, Parthiban P, Jeong YT (2012) BF₃ · SiO₂ is a simple and efficient Lewis acid catalyst for the one-pot synthesis of polyfunctionalized piperidin-4-ones. Monatsh Chem 143:113– 118. doi[:10.1007/s00706-011-0576-5](http://dx.doi.org/10.1007/s00706-011-0576-5)